Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CRVS | US
0.36
6.82%
Healthcare
Biotechnology
30/06/2024
04/10/2024
5.64
5.32
5.85
5.32
Corvus Pharmaceuticals Inc. a clinical stage biopharmaceutical company focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006) an anti-CD73 monoclonal antibody which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818 a covalent inhibitor of ITK which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444) an oral small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182 an antibody designed to block inflammation and myeloid suppression; and CPI-935 an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals Inc. was incorporated in 2014 and is based in Burlingame California.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
74.9%1 month
91.3%3 months
97.1%6 months
87.7%-
-
6.29
0.01
0.01
0.36
-
-
-23.27M
352.79M
352.79M
-
-
-
-
-44.91
3.98
3.25
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.27
Range1M
2.25
Range3M
4.40
Rel. volume
0.55
Price X volume
1.49M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Voyager Therapeutics Inc | VYGR | Biotechnology | 7.04 | 383.91M | 20.96% | 21.67 | 13.99% |
Biomea Fusion Inc. Common Stock | BMEA | Biotechnology | 10.48 | 379.48M | 3.46% | n/a | 9.95% |
ZVRA | ZVRA | Biotechnology | 7.2 | 378.85M | 1.12% | n/a | 183.10% |
C4 Therapeutics Inc | CCCC | Biotechnology | 5.38 | 373.04M | -0.92% | n/a | 27.69% |
Anika Therapeutics Inc | ANIK | Biotechnology | 24.99 | 369.77M | -0.12% | n/a | 13.35% |
Fate Therapeutics Inc | FATE | Biotechnology | 3.22 | 366.69M | 0.31% | n/a | 25.33% |
ITOS | ITOS | Biotechnology | 10.02 | 365.95M | 2.04% | n/a | 0.83% |
INZY | INZY | Biotechnology | 5.17 | 346.90M | 2.78% | n/a | 49.47% |
Nautilus Biotechnology Inc. | NAUT | Biotechnology | 2.71 | 339.86M | -0.73% | n/a | 13.86% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 6.49 | 337.66M | 2.69% | n/a | 0.38% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.36 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 6.29 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 97.07 | 74.67 | Riskier |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 352.79M | 3.73B | Emerging |